Milestone CEO’s 10b5‑1 Sales Raise Questions Amid Quiet Share Decline【Flash】
Milestone Pharmaceuticals CEO sells 43,500 shares under a Rule 10b5‑1 plan – a routine liquidity move, not a bearish sign. Understand the implications for investors.
- Milestone Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read